We are live on ! Find out more
ADAP

Adaptimmune Therapeutics
ADAP

Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

80 hedge funds and large institutions have $229M invested in Adaptimmune Therapeutics in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 26 increasing their positions, 24 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 24

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.37% less ownership

Funds ownership: 12.12% → 11.75% (-0.37%)

6% less funds holding

Funds holding: 85 → 80 (-5)

19% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 16

36% less call options, than puts

Call options by funds: $191K | Put options by funds: $299K

46% less capital invested

Capital invested by funds: $426M → $229M (-$197M)

Holders
80
Holders Change
-5
Holders Change %
-5.88%
% of All Funds
1.26%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
13
Increased
26
Reduced
24
Closed
16
Calls
$191K
Puts
$299K
Net Calls
-$108K
Net Calls Change
-$404K

Top Buyers

Rank Fund Capital Flow
1
LFCM
Long Focus Capital Management
Puerto Rico
+$6.12M
2
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
+$4.38M
3
ECM
Endurant Capital Management
California
+$3.41M
4
Renaissance Technologies
Renaissance Technologies
New York
+$1.44M
5
Two Sigma Investments
Two Sigma Investments
New York
+$712K

Top Sellers

Rank Fund Capital Flow
1
Capital World Investors
Capital World Investors
California
-$30M
2
PHS
PFM Health Sciences
California
-$2.23M
3
Marshall Wace
Marshall Wace
United Kingdom
-$2.13M
4
Millennium Management
Millennium Management
New York
-$529K
5
Morgan Stanley
Morgan Stanley
New York
-$513K
Name Holding Trade Value Shares
Change 		Change in
Stake
EP
26
Eversept Partners
New York
$488K -$301K -111,630 -32%
WM
27
WS Management
Florida
$238K – – –
Two Sigma Advisers
28
Two Sigma Advisers
New York
$216K +$283K +105,000 New
EAM
29
Erste Asset Management
Austria
$185K – – –
ACM
30
ACT Capital Management
Pennsylvania
$185K – – –
Susquehanna International Group
31
Susquehanna International Group
Pennsylvania
$165K -$86.3K -31,981 -29%
Mitsubishi UFJ Asset Management
32
Mitsubishi UFJ Asset Management
Japan
$153K +$13.8K +5,116 +7%
Geode Capital Management
33
Geode Capital Management
Massachusetts
$149K – – –
GCP
34
GSA Capital Partners
United Kingdom
$143K -$39.2K -14,517 -17%
JF
35
Jump Financial
Illinois
$115K -$170K -62,800 -53%
IA
36
Inspire Advisors
Idaho
$93K +$80.2K +29,712 +193%
CSS
37
Cubist Systematic Strategies
Connecticut
$91K -$98K -36,321 -45%
VEA
38
Virtus ETF Advisers
New York
$91K -$7.1K -2,631 -6%
Acadian Asset Management
39
Acadian Asset Management
Massachusetts
$91K +$119K +44,208 New
CM
40
Crestline Management
Texas
$82K +$108K +40,000 New
Daiwa Securities Group
41
Daiwa Securities Group
Japan
$73K +$29.7K +11,001 +45%
II
42
Inspire Investing
Idaho
$66K +$31.6K +11,723 +58%
Janney Montgomery Scott
43
Janney Montgomery Scott
Pennsylvania
$62K – – –
Stifel Financial
44
Stifel Financial
Missouri
$61K -$22.9K -8,500 -22%
PCS
45
Personal CFO Solutions
New Jersey
$54K – – –
VF
46
Virtu Financial
New York
$50K +$66K +24,470 New
Group One Trading
47
Group One Trading
Illinois
$46K +$880 +326 +1%
Citigroup
48
Citigroup
New York
$44K -$23K -8,512 -28%
HAIM
49
Hunter Associates Investment Management
Pennsylvania
$41K +$24.3K +9,000 +82%
LWMG
50
Levy Wealth Management Group
Pennsylvania
$36K +$47.5K +17,590 New
1
2
3 4

ADAP Hedge Fund Activity: Q1 2022 in Review

80 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q1 2022, worth a combined $229M — down 46% from $426M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of ADAP and 13 opened new positions — a net loss of 3 holders — while 24 trimmed existing stakes and 26 added.

The largest buyer was Long Focus Capital Management, adding an estimated $6.12M. The largest seller was Capital World Investors, exiting entirely with an estimated $30M sold.

  • 80 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q1 2022, down from 85 in Q4 2021.
  • Funds reported $229M of Adaptimmune Therapeutics stock for Q1 2022, down 46% quarter-over-quarter.
  • 13 funds opened new Adaptimmune Therapeutics positions in Q1 2022 and 16 closed out, a net change of -3 holders.
  • The largest Adaptimmune Therapeutics buyer in Q1 2022 was Long Focus Capital Management, an estimated $6.12M added.
  • The largest Adaptimmune Therapeutics seller in Q1 2022 was Capital World Investors, an estimated $30M sold.

Based on aggregated 13F filings for Q1 2022.